PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

    Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") and Asterion Cannabis Inc. ("Asterion") announce that they have entered into an option to purchase agreement (the "Option Agreement"), whereby PreveCeutical has granted to Asterion the right and option (the "Option") ...

    2019-08-06 1:59 PM ET
  • PreveCeutical Named in Lawsuit

    Vancouver, British Columbia--(Newsfile Corp. - July 19, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has been named as a defendant in a lawsuit commenced in the Supreme Court of British Columbia (the "Claim") on July 11, 2019 (Tietz and ...

    2019-07-19 7:45 PM ET
  • PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

    Vancouver, British Columbia--(Newsfile Corp. - July 9, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FS

    2019-07-09 8:00 AM ET
  • PreveCeutical Announces Appointment of New Directors

    Vancouver, British Columbia--(Newsfile Corp. - June 21, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the appointments of Keith Anderson and Mark Lotz to the board of directors of the Company (the "Board"), effective immediately.Stephen Van Deventer, PreveCeutical's ...

    2019-06-21 11:08 AM ET
  • PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

    Vancouver, British Columbia--(Newsfile Corp. - June 17, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide positive results from research conducted for its dual gene therapy research program (the "Program").PreveCeutical previousl

    2019-06-17 8:00 AM ET
  • PreveCeutical Secures $300,000 Loan and Resignation of a Director

    Vancouver, British Columbia--(Newsfile Corp. - June 3, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has received a loan in the aggregate amount of $300,000 (the "Loan") pursuant to a loan agreement with the Company's Chairman and Chief Executive Officer, ...

    2019-06-03 8:00 AM ET
  • PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

    Vancouver, British Columbia--(Newsfile Corp. - May 21, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company's research team at the University of Queensland has been granted the necessary approvals from a local hospital's Human Ethics Committee to acquire and use ...

    2019-05-21 8:00 AM ET
  • PreveCeutical Partnership Leads to Two New Patent Filings

    Vancouver, British Columbia--(Newsfile Corp. - April 17, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that the Company's research collaboration with UniQuest and The University of Queensland ("UQ") has led to the filing of two new patent applications for cyclic peptides ...

    2019-04-17 10:35 AM ET